Program
FRSW107
A development code.
Its studies are mostly in Hemophilia A, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hangzhou Gensciences Biopharmaceutical | 22 open or running | phase 3since Jun 15, 2026 | Jun 15, 2026 | Feb 2027phase 3 · NCT07663903 |
| Jiangsu Gensciences lnc. | 21 open or running | phase 3since Oct 26, 2023 | Feb 11, 2022 | Dec 31, 2026phase 3 · NCT06136507 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 11, 2022First study: phase 1 study in Hemophilia ANew to Jiangsu Gensciences lnc.Jiangsu Gensciences lnc. · NCT05251090 · 13 enrolled · China
- Oct 26, 2023Phase 3 study in Hemophilia AJiangsu Gensciences lnc. · NCT06136507 · 76 planned · China
- Jun 15, 2026Hangzhou Gensciences Biopharmaceutical's first studies: 2 phase 3 studies in Hemophilia ANew to Hangzhou Gensciences BiopharmaceuticalHangzhou Gensciences Biopharmaceutical · NCT07663903, NCT07684898
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Hemophilia AJiangsu Gensciences lnc. · NCT06136507
- Feb 2027Primary completion: phase 3 study in Hemophilia AHangzhou Gensciences Biopharmaceutical · NCT07663903
- Mar 9, 2027Primary completion: phase 3 study in Hemophilia AHangzhou Gensciences Biopharmaceutical · NCT07684898
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07684898Hemophilia A · China | 3 | Active, not recruiting | Hangzhou Gensciences Biopharmaceutical | Mar 9, 2027 | 60 |
| NCT07663903Hemophilia A · China | 3 | Active, not recruiting | Hangzhou Gensciences Biopharmaceutical | Feb 2027 | 60 |
| NCT06136507Hemophilia A · China | 3 | Not yet recruiting | Jiangsu Gensciences lnc. | Dec 31, 2026 | 76 |
| NCT05251090Hemophilia A · China | 1 | Completed | Jiangsu Gensciences lnc. | Nov 15, 2021 | 13 |
How it is read
Names in the registry
- “FRSW107”, 4 entries
Codes read as this program: FRSW107.
Conditions, from the studies’ own filings
- Hemophilia A, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.